Sarcoidosis Clinical Trial
Official title:
Physical Training in Sarcoidosis Patients With Fatigue Complaints
Verified date | September 2014 |
Source | Maastricht University Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Exercise intolerance, muscle weakness and fatigue complaints are frequent and persistent
problems in sarcoidosis. These physical impairments are disabling and affect quality of life
in a negative way. The aetiology of these physical impairments is multifactorial. Physical
inactivity can cause deconditioning, resulting in more perceived fatigue and muscle weakness.
These symptoms may be partially reversible following a structured physical training program.
However, scientific studies about physical training in sarcoidosis are lacking. Therefore,
the aim of the present study is to examine the changes in fatigue complaints, physical
functioning and quality of life (QOL) in patients with sarcoidosis following a 13-week
physical training program.
After obtaining written informed consent, sarcoidosis patients will start a 13-week physical
training program for three times a week. This training program includes peripheral muscle
training for both the upper and lower extremities (starting at 40% of the multiple-repetition
maximum) and endurance training consisting of walking on a treadmill (starting at 60% of the
speed of the 6-minute walk test) or cycling on a ergometer (starting at 50% of the Wmax).
Participants will be assessed at baseline (week 0), at the end (13 weeks) and 3 months after
ending the training. During these assessments, patients perform muscle strength (m.
quadriceps and m. biceps) and exercise tests (six-minute walk test and submaximal endurance
cycling test). They also complete several questionnaires:
Fatigue Assessment Scale (FAS), World Health Organization Quality of Life assessment
instrument-BREF (WHOQOL-BREF), Small Fiber Neuropathy Screening List (SFNSL), Medical
Research Council (MRC), Visual Analogue Scale (VAS) and Hospital Anxiety and Depression Scale
(HADS)
Status | Completed |
Enrollment | 40 |
Est. completion date | May 2014 |
Est. primary completion date | April 2014 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Patients are diagnosed with sarcoidosis according to the WASOG guideline. - Fatigued patients ((FAS-score = 22 points) and/or a reduced six-minute walking distance (predicted six-minute walking distance -50 m). - Patients who signed the consent form and are able to participate in a training program. - Minimum age 18 years and maximum age 70 years. - Clinically stable: no exacerbation of complaints, or changes in initiated therapeutic management during the preceding 3 months. Exclusion Criteria: - Patients with a cognitive failure, making them unable to understand questionnaires and instructions. - Patients with a oncological, cardiac, neurological or orthopedic history making them unable to participate in a training program. - Patients who are unfamiliar with the Dutch language, disabling them to understand questionnaires and instructions. - Patients who participated in a physical training program six months prior to inclusion. |
Country | Name | City | State |
---|---|---|---|
Netherlands | Fysiomedica | Geleen | Limburg |
Lead Sponsor | Collaborator |
---|---|
Maastricht University Medical Center | ild care foundation |
Netherlands,
Marcellis RG, Lenssen AF, de Vries GJ, Baughman RP, van der Grinten CP, Verschakelen JA, De Vries J, Drent M. Is there an added value of cardiopulmonary exercise testing in sarcoidosis patients? Lung. 2013 Feb;191(1):43-52. doi: 10.1007/s00408-012-9432-6. Epub 2012 Nov 9. — View Citation
Marcellis RG, Lenssen AF, Elfferich MD, De Vries J, Kassim S, Foerster K, Drent M. Exercise capacity, muscle strength and fatigue in sarcoidosis. Eur Respir J. 2011 Sep;38(3):628-34. doi: 10.1183/09031936.00117710. Epub 2011 Mar 24. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cange in Fatigue Assessment Scale (FAS)at 3 months after end of the training | The 10-item FAS is a fatigue scale. Each item has a 5-point rating scale and FAS scores range from 10-50. FAS scores <22 indicate nonfatigue persons and scores of 22-34 indicate fatigued persons. | baseline (week 0), at the end (week 13) and 3 months after ending the training |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04008069 -
Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis
|
Phase 2 | |
Recruiting |
NCT02807025 -
Nasal, Tracheal and Bronchial Mucosal Lining Fluid(MLF) Sampling From Patients With Respiratory Diseases
|
N/A | |
Completed |
NCT01615484 -
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
|
N/A | |
Completed |
NCT00373555 -
Endobronchial Ultrasonography in the Diagnosis of Sarcoidosis
|
N/A | |
Completed |
NCT00274352 -
A Study of Adalimumab to Treat Sarcoidosis of the Skin
|
Phase 2 | |
Completed |
NCT00326534 -
Rickettsial Genesis to Sarcoidosis in Denmark
|
N/A | |
Recruiting |
NCT00470327 -
A Study of the Natural Progression of Interstitial Lung Disease (ILD)
|
||
Completed |
NCT00512967 -
The Occurence of Inflammation and Oxidative Stress in Lung Diseases
|
N/A | |
Recruiting |
NCT01745237 -
Delayed-Enhancement Cardiovascular Magnetic Resonance in Patients With Sarcoidosis
|
||
Completed |
NCT00369980 -
Diagnostic Usefulness of Fluorine–18-α–Methyltyrosine PET in Combination With 18F-FDG in Sarcoidosis Patient
|
N/A | |
Completed |
NCT00366509 -
Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System Diseases
|
||
Completed |
NCT00379275 -
Eye and Immunogenetic Features of Sarcoidosis
|
N/A | |
Completed |
NCT06396910 -
TB and Sarcoidosis Granuloma
|
||
Completed |
NCT04156789 -
Obstructive Sleep Apnoea in Sarcoidosis
|
||
Recruiting |
NCT02916459 -
EBUS-TBNA vs Flex 19G EBUS-TBNA
|
N/A | |
Recruiting |
NCT02827734 -
Evaluation of Novel Lung Function Parameters in Patients With Interstitial Lung Disease (ILD)
|
||
Completed |
NCT02546388 -
Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis
|
N/A | |
Completed |
NCT01687517 -
Efficacy and Safety of Influenza Vaccine During Sarcoidosis
|
Phase 3 | |
Completed |
NCT01139710 -
Sarcoidosis-associated Pulmonary Hypertension
|
N/A | |
Terminated |
NCT00747461 -
Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD")
|
Phase 4 |